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Purpose: There are no selective antagonists for the metabotropic nucleotide P2Y2 receptor subtype. This implies that it
is not possible to demonstrate the importance of such a receptor in the relevant process of corneal wound healing. Therefore,
we have cloned and designed a small interference RNA (siRNA) against the rabbit P2Y2 receptor (P2Y2-R) mRNA, which
clearly demonstrates the importance of this receptor in the process of wound healing triggered by nucleotides and
dinucleotides both in vitro and in vivo.
Methods: Rabbit P2Y2-R cDNA was cloned using a combination of degenerate reverse transcription polymerase chain
reaction (RT-PCR) and rapid amplification of cDNA ends (RACE). To test the efficacy of synthesized siRNAs targeting
P2Y2-R, immunocytochemistry, immunohistochemistry, and quantitative RT-PCR (qRT–PCR) assays were performed.
Migration assays were performed both in vitro and in vivo by wounding the epithelium with a pipette tip and n-heptanol,
respectively. These wounds were performed 72 h after siRNA transfection either in the presence or the absence of the
P2Y2 agonist, 100 μM Ap4A (diadenosine tetraphosphate).
Results: The cloned receptor presents 93% homology compared to the human gene. Two siRNAs were designed and
synthesized against a rabbit P2Y2-R sequence. After transfection (in vitro assays) or topical instillation (in vivo assays),
we demonstrated P2Y2-R siRNA efficient transfection/delivery and its efficient gene silencing. Clear reduction of P2Y2-
R expression was observed at both the mRNA and protein levels in corneas treated with siRNA. In vitro and in vivo
migration analysis showed that the silencing process has concomitantly reduced the ability of corneal cells to close the
wounds in the presence of the Ap4A. In addition, both synthesized siRNAs exert a delay effect on the Ap4A-induced
migration rate in vitro. These results suggest the absence of non-specific (off-target) effects by our siRNA.
Conclusions: The application of P2Y2-R siRNA has demonstrated the role of this receptor in the accelerating effect of
diadenosine tetraphosphate (Ap4A) on the corneal wound healing process.
Epithelial cell repair is a biochemical process which relies
on  the  activation  of  intracellular  pathways  triggered  by
receptors  stimulated  by  extracellular  messengers.  In  the
cornea, this physiologic process (corneal epithelial renewal)
is essential to form a regular refractive surface and to form a
barrier  that  contributes  to  corneal  deturgescence  and  the
prevention of pathogen invasion [1,2]. The renewal of the
corneal epithelium is sustained by the migration, proliferation,
and differentiation of stem cells present in the limbus.
Many substances present in tears or the aqueous humor
or released from corneal nerves stimulate the wound healing
process after ocular surface injuries [3,4]. Since the corneal
surface is frequently damaged by refractive surgery, chemical
trauma, inflammation, or infection, mechanisms by which
epithelial receptors and its ligands elicit control of corneal
epithelial renewal/wound healing have been investigated.
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Among the naturally occurring substances recently found
to modify the rate of healing, nucleotides and dinucleotides
present in tears have been shown to be very active [4,5].
Nucleotides influence the corneal epithelial cells healing rate
by either accelerating or decelerating the healing process. The
way the wound healing process takes place depends on the
metabotropic  P2  receptors  that  are  activated.  It  has  been
tentatively suggested that the activation of P2Y2 receptors
accelerates the rate of corneal epithelial cell migration while
the stimulation of a P2Y6 does the opposite [6]. The positive
role of the P2Y2 receptor (P2Y2-R) is a matter of interest in
understanding  how  this  receptor  triggers  the  intracellular
machinery that produces an increase in the rate of healing.
However, due to the lack of selective antagonists [7-9], it is
not possible to prove the involvement of P2Y2-R in the corneal
wound healing process.
RNA interference (RNAi) technology has proven to be
an efficient tool to suppress the expression of targeted genes
in  vitro  and,  more  recently,  in  vivo.  In  vivo  assays  have
allowed us to evaluate the therapeutic potential of synthetic
small interfering RNAs (siRNAs). For a review of in vivo use
of siRNA, see [10]. Ocular delivery of siRNAs has also been
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1169performed for both basic biology research and to develop new
treatments for ocular diseases [11,12].
The lack of selective antagonists to block the action of
P2Y2-R as previously commented led us to investigate the role
of P2Y2-R in corneal wound healing by designing a siRNA
capable to eliminate the expression of this protein in corneal
cells. Therefore, in this experimental work, we describe the
cloning of rabbit P2Y2-R and the design of a siRNA against
P2Y2-R mRNA, which clearly demonstrates the importance of
this receptor in the process of wound healing triggered by
nucleotides and dinucleotides both in vitro and in vivo.
METHODS
Animals: Male, adult New Zealand White rabbits were used
in these studies. All the animals were kept in individual cages
with free access to food and water under controlled cycles (12
h  light:12  h  dark),  and  the  experimental  procedures  were
performed in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research and the
European Communities Council Directive (89/609/EEC).
Corneal epithelial cell culture: The rabbit corneal cell line,
SIRC (Statens Seruminstitut Rabbit Cornea), was obtained
from ATCC (LGC Promochem SL., Barcelona, Spain). SIRC
cells were maintained in minimum essential medium (MEM)
with Earle’s salts, L-glutamine, and non-essential amino acids
(Invitrogen, Paisley, UK) supplemented with 10% activated
FBS (Invitrogen), and incubated at 37 °C in 5% CO2 and 95%
humidity until confluence.
Cloning and sequencing: The rabbit P2Y2 receptor cDNA was
cloned  using  a  combination  of  degenerate  reverse
transcription polymerase chain reaction (RT-PCR) and rapid
amplification  of  cDNA  ends  (RACE).  Total  RNA  was
extracted from SIRC cells using the RNeasy Mini Kit (Qiagen,
Barcelona, Spain). For first-strand cDNA synthesis, 5 µg of
total  RNA  was  retrotranscribed  using  the  SuperScript  III
Reverse Transcriptase and oligo(dT; Invitrogen. The initial
PCR was performed with a pair of degenerate primers based
on  two  highly  conserved  regions  of  P2Y2-R  sequences
(forward, 5′-TGC AAG CTG GTG CGY TTC CTY TTC
TA-3′ and reverse, 5′-AGY CTC TGC CCW GCC AGG AAG
TAG AG-3′). The PCR amplification was performed in a 50
µl  volume  with  2  µl  of  cDNA,  1X  PCR  buffer,  2  mM
MgCl2, 200 µM each dNTPs, 0.6 µM of each primer, and
0.025 U/µl of AmpliTaq Gold® DNA polymerase (Applied
Biosystems, Foster City, CA). The thermal cycling conditions
for PCR were 95 °C for 5 min; 5 cycles of 95 °C for 45 s and
72 °C for 2 min each; 5 cycles of 95 °C for 45 s, 70 °C for 45
s, and 72 °C for 2 min each; and 25 cycles of 95 °C for 45 s,
64 °C for 45 s, and 72 °C for 2 min each.
The PCR products of the expected size were extracted
from 1.5% low-melt agarose gels with the QIAquick Gel
Extraction Kit (Qiagen), cloned with TOPO TA Cloning Kit
(Invitrogen), and then sequenced. After sequencing, a new
pair of primers was synthesized (forward, 5′-TCA ACG AGG
ACT TCA AGT AYG T-3′ and reverse, 5′-CTG ATA CAA
GTG AGG AAG AGG AT-3′) and used to obtain contiguous
sequence information. PCR amplification was performed in a
50 µl volume with 2 µl of cDNA, 1X PCR buffer, 2 mM
MgCl2, 200 µM each dNTP, 0.4 µM of each primer, and
0.025U/µl of AmpliTaq Gold® DNA polymerase (Applied
Biosystems). The thermal cycling conditions for PCR were
95 °C for 5 min; 10 cycles of 95 °C for 45 s, 60 °C for 45 s
(−1 °C/cycle), and 72 °C for 1 min each; 30 cycles of 95 °C
for 45 s, 50 °C for 45 s, and 72 °C for 1 min each; and 1 cycle
of 72 °C for 7 min each.
To obtain the 5′-end of the coding sequence of rabbit
P2Y2-R  cDNA,  we  used  a  FirstChoice  RLM-RACE  Kit
(Applied  Biosystems).  In  brief,  10  µg  of  total  RNA  was
dephosphorylated,  decapped,  and  ligated  to  the  5′-RACE
adaptor. Ligated RNA was reverse transcribed with random
decamers and amplified by nested PCR. The first round of
PCR was performed with a rabbit P2Y2-R specific reverse
primer (5′-AGT GGT CGC GGG CGT AGT AGT AG-3′),
and a forward adaptor primer provided in the kit. One µl of
the obtained PCR product was used as a template for a second
round of PCR. The second round of PCR was performed with
a new rabbit P2Y2-R specific reverse primer (5′-ACA CGG
CCA  GGT  GGA  ACA  TGT  A-3′)  and  an  inner  forward
adaptor primer provided in the kit. The PCR products of the
expected size were purified from agarose gels, cloned, and
sequenced. DNA sequencing was performed by the Unidad
de  Genómica  (Parque  Científico  de  Madrid-Universidad
Complutense, Madrid, Spain). The nucleotide sequences were
compared  by  searching  the  GenBank  databases  with  the
BLAST program. Alignment of amino acid sequences were
performed with the Clustal W2 program [13] using default
parameters.
To design P2Y2-R specific siRNA duplexes, the rabbit
P2Y2-R  coding  sequence  (GenBank  EU886321)  was
submitted to the Ambion siRNA target Finder website for
siRNA prediction. Two sequences of nine (maximum GC
content 60%) suggested candidates were selected. Nucleotide
sequences of the siRNA target sites were as follows: P2Y2-R
siRNA #1, 5′-AAT GAG GAC TTC AAG TAC GTG-3′ (see
Figure 1A) and P2Y2-R siRNA #2, 5′-AAC CTG TAC TGC
AGC ATC CTC-3′ (Figure 1A). Both siRNAs were obtained
from Applied Biosystems in annealed and lyophilized forms
and were suspended in RNase-DNase-free water or in 0.9%
NaCl before in vitro or in vivo use. In addition, a Cy3-labeled
non-silencing siRNA, used to determine optimal conditions
for siRNA transfection, was also purchased from Applied
Biosystems.  Transfection  complexes  were  prepared  in  an
Opti-MEM serum free medium (Invitrogen) by mixing 3 µl
of siPORT NeoFX transfection reagent (Applied Biosystems)
and 300 nM of P2Y2-R siRNA or just in RNase-DNase-free
water (transfection reagent alone was the control). SIRC cells
(50,000 cells per well) were plated in a 24 well format after
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incubated  for  72  h  and  analyzed  by  migration  assay.  To
evaluate transfection efficiency, SIRC cells were incubated
for  24  h  with  30  nM  Cy3-labeled  non-silencing  siRNA,
washed  briefly  in  PBS,  and  then  fixed  in  4%
paraformaldehyde  for  15  min.  Nuclei  localization  was
analyzed  using  PicoGreen  staining  (1:200).  PicoGreen
(Invitrogen) is a fluorescent DNA-specific dye that has been
recently used to analyze DNA distribution in permeabilized
cells [14,15]. Finally, cells were visualized by a confocal
microscope  (Axiovert  200M;  Carl  Zeiss  Meditec  GmbH,
Jena, Germany), equipped with a Pascal confocal module
(LSM  5;  Carl  Zeiss  Meditec  GmbH).  Cell  viability  was
assessed by means of the trypan blue test (Sigma-Aldrich, St.
Louis, MO ).
Immunocytochemistry: SIRC cells were transfected for 72 h
with the P2Y2-R siRNA or the transfection reagent alone. The
cells were then washed with 10X PBS and fixed for 15 min at
room temperature with 4% paraformaldehyde in 0.15 M PBS.
Cells were washed again with 10X PBS and permeabilized
with blocking solution (1X PBS, 3% BSA, Triton X-100, 5%
FBS) for 1 h at room temperature to block the non-specific
binding sites. Cells were then washed with 1X PBS and 3%
BSA and incubated with primary goat polyclonal anti-P2Y2-
R (1:50; Santa Cruz Biotechnology, Santa Cruz, CA) or with
1X  PBS  and  3%  BSA  for  negative  controls  at  room
temperature for 1 h. Cells were washed twice in 1X PBS and
3% BSA and incubated with the secondary antibody donkey
anti-goat IgG-FITC (1:200; Santa Cruz Biotechnology) for 1
h at room temperature. Finally, three washes in 1X PBS were
performed, and coverslips were applied to the slides with
Vectashield  mounting  medium  (Vector  Laboratories  Inc.,
Burlingame,  CA).  The  cells  were  observed  by  confocal
microscope  (Axiovert  200M;  Carl  Zeiss  Meditec  GmbH)
equipped with a Pascal confocal module (LSM 5; Carl Zeiss
Meditec  GmbH).  All  images  were  managed  with  the
accompanying Pascal software.
Cell wounding and migration assays: After transfection for
72 h with P2Y2-R siRNA or transfection reagent alone, cell
monolayers  were  wounded  and  treated  with  100  µM  of
diadenosine  tetraphosphate  (Ap4A;  Sigma-Aldrich)  as
previously described [6]. Briefly, SIRC confluent monolayers
were wounded by scraping the cell monolayer with a pipette
tip.  The  initial  wound  size  and  shape  were  comparable
(60,000–80,000 μm2) to take into account the variations in
wound  closure  due  to  size,  so  healings  shared  the  same
Figure 1. Rabbit P2Y2-R cDNA. A: Nucleotide sequence and deduced amino acid sequence of cloned rabbit P2Y2-R are shown. siRNA-target
sequences are indicated with solid lines. B: Alignment of the rabbit deduced amino acid sequence with the human P2Y2-R sequence is displayed.
Identical amino acids are shaded. Protein database searches revealed that the deduced sequence had the highest amino acid identity with human
P2Y2-R (93%). These sequences are available under GenBank accession number EU886321 (rabbit) and NP_788086.1 (human).
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[16]. Wound area measurements (for each treatment) were
collected  from  four  different  wells  and  averaged  as  one
measurement (mean±SEM.). Cells were challenged with the
dinucleotide  dose  for  2  min  in  Locke  medium  to  avoid
interference from components of media such as DMEM [17].
After this incubation, cells were washed and fresh MEM was
added.  A  control  experiment  (cells  transfected  with  the
transfection  reagent  alone)  was  performed  by  challenging
wounded  monolayers  with  Locke  medium  (repeated  4
independent times). The dinucleotide dose was added to the
wound when wound was first made (0 h) and 6 h after, as
previously described for rabbits [4]. Images were captured
every 2 h for the first 10 h and at 24 h after the beginning of
the experiment. Wounds were measured with LSM 5 Pascal
software  (Zeiss  Axiovert  200M  microscope).  Between
different  image  collections,  cells  were  kept  in  the  CO2
incubator at 37 °C in 5% CO2 and 95% humidity.
In vivo delivery of P2Y2-R siRNA and wounding procedure:
The siRNA was applied in one eye in 10 nmol 0.9% NaCl
drops (40 µl volume instilled) once a day for four consecutive
days. The contralateral eye received the same volume of saline
solution (0.9% NaCl). This method of delivery is particularly
useful  considering  that  the  cornea  is  the  most  superficial
ocular layer. Slit-lamp biomicroscopy was performed during
the instillation process to evaluate possible changes in the
cornea.
Corneal wounds were performed 10 h before the fourth
siRNA  instillation.  After  topical  anesthesia  (0.4%
oxybuprocaine and 1% tetracaine; Alcon Cusi, Barcelona,
Spain), corneal wounds were made to the epithelium of both
eyes by applying a 3 mm disc of Whatman X1 paper soaked
in n-heptanol (Sigma-Aldrich) as previously described [4].
Briefly, discs were place in the center of the cornea and left
there for 30 s [18]. After removal of the disc, the eyes were
washed with isotonic saline solution.
Immunohistochemistry: Twelve, twenty-four, and thirty-six h
after  epithelium  wounding,  rabbits  were  euthanized  with
sodium pentothal and their eyes were enucleated. Corneas
were dissected and fixed with 4% paraformaldehyde in 0.15
M PBS at 4 °C for 6 h. After fixation, corneas were embedded
in  Jung  Tissue  Freezing  Medium  (Leica  Microsystems,
Barcelona, Spain), and 10 μm sections were cut. The P2Y2-R
immunocytochemical  assay  was  performed  as  previously
described for cells[6]. Briefly, sections were permeabilized
with blocking solution (1X PBS, 3% BSA, Triton X-100, and
5% FBS) for 1 h to block non-specific binding. After washing
with  1X  PBS  and  3%  BSA,  sections  are  incubated  with
primary goat polyclonal anti-P2Y2-R (1:50) or 1X PBS and
3% BSA for negative controls overnight at 4 °C. Sections were
washed twice in 1X PBS and 3% BSA and incubated with the
secondary antibody, donkey anti-goat IgG-FITC (1:200), for
1 h at room temperature. Finally, after washing in 1X PBS,
slices were mounted with Vectashield mounting medium and
observed under confocal microscope (Axiovert 200M; Carl
Zeiss  Meditec  GmbH)  equipped  with  a  Pascal  confocal
module (LSM 5; Carl Zeiss Meditec GmbH). All images were
managed with the accompanying Pascal software.
Quantitative real-time RT–PCR: To validate the efficiency of
P2Y2-R  siRNA  and  its  on-target  effect,  we  measured  the
reduction  of  target  mRNA  level  in  treated  corneas  by
quantitative  RT-PCR  (qRT–PCR).  Corneal  impression
cytology samples were collected 48, 72, and 96 h after first
siRNA  instillation.  After  topical  anesthesia  (0.4%
oxybuprocaine  and  1%  tetracaine;  Alcon  Cusi),  a  disc  of
cellulose  acetate  filter  paper  (HAWP304F0;  Millipore,
Bedford, EUA) was applied over the central corneal surface
for  15  s.  The  cellulose  acetate  filter  was  immediately
transferred into a tube containing 350 µl of RNA extraction
reagent (RNeasy Mini Kit; Qiagen). All samples were stored
at  −80  °C  until  time  of  analysis.  After  vortex  lysis/
homogenization, we followed the manufacturer’s protocol. To
avoid genomic DNA contamination, we performed the on-
column DNA digestion step. For first-strand cDNA synthesis,
30 µl of total RNA was retrotranscribed using High Capacity
cDNA RT kit (Applied Biosystems). Relative quantification
of gene expression was performed using real-time RT–PCR
on  an  ABI  Prism  7300  Real-Time  PCR  System  (Applied
Biosystems)  with  Quantitect  SYBR  Green  Kit  (Qiagen)
according  to  the  manufacturer’s  protocol.  The  following
primers were used in real-time PCR amplification: P2Y2-R
specific forward, 5′-TGG AGC CGT CTC TAA CCC TGA-3′
and P2Y2-R specific reverse, 5′-GCT GGC ACG CTG AAC
CAG TA-3′). The level of P2Y2-R mRNA was normalized to
the housekeeping gene, HPRT1 (HPRT1-specific forward, 5′-
CTG  GCA  AAA  CAA  TGC  AGA  CCT-3′  and  HPRT1-
specific reverse, 5′-GTC CTT TTC ACC AGC AGG CTT-3′).
The remaining percentage of P2Y2-R mRNA was calculated
using the Pfaffl method [19].
In vivo migration assays: Rabbit corneas were treated with
P2Y2-R siRNA #2 once a day for three days before the wounds
were made, and the fourth dose of siRNA was applied 10 h
after the wounds were made. Ap4A (100 μM) was topically
applied to the wounds in Ap4A and siRNA+Ap4A corneas
every 6 h (starting 10 h after the wound was made), and some
animals were used as controls and was just treated with 0.9%
saline.
To evaluate the closure of the wounds, these were stained
with 2% fluorescein every 2 h with a gap of 10 h between the
making  of  the  original  wounds  until  the  beginning  of
measurements. This corresponds to the lag phase of the in vivo
corneal wound healing process. The eyes were examined with
a Topcon SL-8Z slit lamp (Topcon, Barcelona, Spain). Images
were taken, managed, and analyzed with the IMAGEnet 2000
system (Topcon).
Analysis  of  data:  P2Y2-R  down-regulation  after  siRNA
transfection was determined by densitometric quantification
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independent  experiments.  In  each  case,  the  results  were
expressed as mean fluorescence intensity (MFI)±SEM and
represented  in  arbitrary  units.  A  correlation  between
fluorescence  intensities  and  the  amount  of  receptors  was
performed.
To model the nonlinear decrease in wound area during
epithelial healing, the constant velocity method previously
described [20] was used with some modifications. Briefly,
estimated migration rates (EMR) were determined by linear
regression  of  the  decrease  in  wound  area  during  10  h  of
measurements  and  were  obtained  by  the  slope  of  the
regression line expressed as the percentage of area decrease
per hour. The total time of wound closure (estimated healing
time, EHT) was calculated by the extrapolation of the best fit
of the regression line during the healing phase until there was
100% closure of each wound tested.
When we represent linear regression of the decrease in
the wound area, data are expressed as a percentage of the
initial  wound  width  (at  0  h)  to  normalize  variability  in
wounding from well to well and experiment to experiment
following the same strategy as described by other authors
[21,22].
EMR  and  EHT  in  treated  and  control  wounds  were
compared using ANOVA test. Average values were expressed
as mean±SEM. The levels of significance for the differences
are indicated in each case in the figure captions.
RESULTS
Cloning of rabbit P2Y2-R: To determine the role of P2Y2-R in
Ap4A-induced  rabbit  corneal  epithelial  cell  migration  by
siRNA technology, we previously cloned the rabbit P2Y2-R
cDNA. Based on the conserved regions of coding sequences
for human, rat, mouse, and pig P2Y2-R, degenerate primers
were designed and used for initial RT–PCR experiments with
total RNA isolated from SIRC cells. After sequencing PCR
products, a new pair of primers was synthesized and used to
obtain  contiguous  sequence  information.  Finally,  the
sequences  obtained  from  RT–PCRs  were  used  to  design
specific primers to rabbit P2Y2-R to facilitate amplification of
5′-end  cDNA  (5′-RACE).  Assembly  of  the  sequences
obtained  yielded  a  sequence  of  1,094  bp  (GenBank
EU886321).  Protein  database  searches  revealed  that  the
deduced sequence had the highest amino acid identity with
human P2Y2-R (93% identity; see Figure 1B).
Efficiency of siRNA transfection into SIRC cells: Preliminary
studies were performed to confirm siRNA transfection. Cells
were  incubated  for  24  h  with  30  nM  Cy3-labeled  non-
silencing  siRNA.  Cultures  were  then  washed,  fixed,  and
visualized by fluorescence microscopy. The presence of Cy3-
positive cells indicated successful siRNA transfection (data
not shown). In addition, the cell viability assay demonstrated
that under these transfection conditions, SIRC cells were not
significantly affected (81% cell viability).
Safety of in vivo siRNA delivery: To confirm the absence of
corneal  changes  after  frequent  instillations  of  siRNA,  we
performed a biomicroscopic examination of the treated eyes.
Neither corneal inflammation, cataract, or any other ocular
alteration were observed throughout siRNA administration
(results not shown).
Inhibition of P2Y2-R expression by siRNA: 
To test the efficacy of synthesized siRNAs targeting P2Y2-R,
immunocytochemistry (ICC), immunohistochemistry (IHC),
and qRT–PCR assays were performed.
Cells were transfected with 300 nM P2Y2-R siRNA #1,
300 nM P2Y2-R siRNA #2, or the transfection reagent alone
(control) for 72 h and then processed for ICC. Staining for
P2Y2  receptor  was  reduced  in  cells  incubated  with  both
P2Y2-R siRNA #1 (data not shown) and P2Y2-R siRNA #2
transfected cells. The P2Y2-R reduction obtained with P2Y2-R
siRNA #2 (Figure 2A) was greater than the observed reduction
for P2Y2-R siRNA #1 (result not shown). Therefore, according
to the in vitro effect of siRNA on migration rate, we chose
P2Y2-R siRNA #2 for the in vivo studies.
A  qualitative  measure  of  the  remaining  P2Y2-R  was
performed from the fluorescence signal intensity in both the
control and siRNA-transfected cells as described in Methods.
Figure 2B shows a plot of the amount of P2Y2-R receptor in
each case. The amount of P2Y2-R in the control cells was
1698.82±12.66 while in P2Y2-R siRNA #2-transfected cells,
the amount of P2Y2-R was 547.04±6.78 (p<0.0001). These
data indicate that the P2Y2-R levels were significantly reduced
to approximately 32% of control levels by P2Y2-R siRNA #2.
The effect of the siRNA against P2Y2-R was tested in
living animals. Prior to that assay, corneas were treated to
identify the localization of P2Y2-R. As we can observe in
Figure 2C, P2Y2-R signaling is localized only in the outer
layer of the epithelium, this signal being higher in control
corneas than in Ap4A-treated corneas 24 h after wounding
(1481.93±34.20  for  control  and  1149.46±28.04  for  Ap4A,
p<0.001;  Figure  2C,  upper  panel).  Thirty-six  h  after  the
wounds were performed, P2Y2-R staining was similar to the
24 h results (1400.05±19.49 for control and 1347.70±19.95
for Ap4A; Figure 2C, lower panel). When the experiment was
performed on living animals, the profile of P2Y2-R expression
in siRNA #2-treated animals presented a marked reduction 24
h after the wound was performed (189.36±10.73, p<0.001)
compared  to  the  control  and  Ap4A-treated  corneas.  The
analysis for a longer period of time (36 h after the wound)
demonstrated a full recovery of the P2Y2 signaling, similar to
the control (1424.14±14.1; Figure 2D).
Concerning the results 12 h after the wound, P2Y2-R
staining in the three different treatments were similar to those
obtained for 24 h after wounding (data not shown). These
results  indicate  that  silencing  P2Y2-R  in  our  model  was
detected 24 h after the wound was performed. Nevertheless,
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made.
Quantification of siRNA #2 silencing efficiency was also
performed by qRT–PCR. As shown in Figure 3, significant
P2Y2-R mRNA knockdown was observed after 48 and 72 h of
the first instillation (23.00%±5.65% and 10.36%±4.47% of
P2Y2-R mRNA remaining, respectively; p<0.001). However,
at 96 h (36 h after wound injury), the effect at the mRNA level
disappears.
P2Y2-R siRNA counteract the effect of Ap4A on corneal wound
healing:  In  a  previous  work,  we  have  demonstrated  the
Ap4A-accelerating effect on rabbit corneal wound healing and
provided  pharmacological  evidence  for  P2Y2-R  mediation
[6].  To  know  the  role  of  rabbit  P2Y2-R  in  Ap4A-re-
epithelialization process, a migration assay was performed on
cells transfected with P2Y2-R siRNA #1 and P2Y2-R siRNA
#2.
Seventy-two  h  post-transfection,  cells  were  wounded
with a pipette tip in the presence or absence of Ap4A. Graphics
in  Figure 4A show  the variation of  the wounded  area versus
time,  and  Figure  4B  shows  the  estimated  migration  rates
(EMR) of control cells (treated with the transfection reagent,
siPORT, alone), cells treated with Ap4A (100 µM) and P2Y2-
R 2 siRNA #1-, and P2Y2-R siRNA #2-transfected cells treated
with Ap4A (100 µM; repeated tour times for each siRNA).
Ap4A  significantly  increased  the  estimated  migration  rate
(3.03%±0.11%)  when  compared  to  the  control  (1.08%
±0.06%; p<0.0001). This represents a concomitant decrease
in the estimated healing time (EHT) with closure of the wound
occurring  56  h  earlier  than  in  the  absence  of  any  added
substance. In the case of P2Y2-R siRNA #1+Ap4A-treated
cells, we found an EMR decrease (1.37%±0.21%) and the
concomitant EHT increase (74 h) when compared with just
Ap4A-treated cells. On the other hand, treatment with P2Y2-R
siRNA #2 and Ap4A caused a high decrease in EMR (1.19%
±0.10%; p<0.001) when compared to just Ap4A-treated cells
and a concomitant increase in EHT (86 h), which were similar
to the EMR and EHT values found in control wounds (Figure
4B). All these results confirm the P2Y2-R silencing efficiency
of P2Y2-R siRNA #2 and also the involvement of P2Y2-R in
the Ap4A re-epithelialization process.
Figure 2. P2Y2-R immunostaining of transfected cells and treated corneas. A: SIRC cells were incubated for 72 h with transfection reagent
alone (control) or with P2Y2-R siRNA #2 and then processed for ICC (40X magnification). B: The chart shows P2Y2-R staining intensity
quantification of control and P2Y2-R siRNA transfected cells 72 h post-transfection. C: A series of micrographs shows the P2Y2-R signal in
corneas treated with 0.9% saline, 100 μM Ap4A, and siRNA+100 μM Ap4A while we can observed the nuclear staining for DAPI in blue (40X).
D: The graph shows the P2Y2-R intensity signal in the three different treatments at 24 h and 36 h after wounding. Three asterisks mean p<0.001
when compared to the control. Green fluorescence (FITC) localizes P2Y2-R.
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1174After  verifying  the  effect  of  P2Y2-R  siRNA  #2
transfection on SIRC cells, we wanted to correlate this effect
with siRNA in vivo migration assays. Figure 5A shows a
series of images where we can demonstrate the closure of
corneal wounds after the three different treatments (control
with 0.9% saline, 100 μM Ap4A, and siRNA+100 μM Ap4A).
We  can  observe  that  after  the  challenge  with  Ap4A,  the
migration rate is accelerated compared to the control wounds
while the treatment with siRNA+Ap4A produces a dramatic
delay in migration.
This can also be observed in Figure 5B where a plot for
variation in wounded area versus time and a plot of EMR for
the three treatments are shown. Ap4A (100 μM) significantly
increased EMR (2.44%±0.10%; p<0.05) in contrast to the
control  wounds  (1.55%±0.19%)  with  the  concomitant
decrease in EHT (from 76 h for control to 55 h for Ap4A). On
Figure  3.  Quantification  of  P2Y2-R
mRNA  levels  by  qRT–PCR  analysis.
Corneal  impression  cytology  samples
were collected at 48, 72, and 96 h after
the  first  siRNA  instillation  and  then
submitted to total RNA isolation. After
retrotranscription, we measured P2Y2-R
mRNA knockdown in corneas treated
with  siRNA  #2.  Values  derived  from
qRT–PCR  results  from  untreated
corneas are set as 100%, and the relative
expressions  of  corneas  treated  with
siRNA  are  indicated.  Three  asterisks
indicate p<0.001 when compared to the
control.
Figure 4. Effect of P2Y2-R siRNA on
Ap4A-induced  migration  of  corneal
epithelial  cells.  SIRC  cells  were
incubated  for  72  h  with  transfection
reagent alone (control), P2Y2-R siRNA
#1,  or  P2Y2-R  siRNA  #2  and  then
wounded  with  a  pipette  tip  in  the
presence  or  absence  of  Ap4A.  The
graphs (A and B) show the variation of
the wounded area versus time and the
estimated  migration  rates  (EMR)  of
cells  transfected  with  siRNA  1  and
siRNA 2, respectively, in the presence
of Ap4A (P2Y2-R siRNA+Ap4A). Ap4A
accelerated the rate of healing in cells
transfected  with  transfection  reagent
alone  (control+Ap4A)  compared  with
the  rate  of  both  P2Y2-R  siRNA-
transfected  cells  in  the  presence  of
Ap4A  (P2Y2-R  siRNA+Ap4A).  Three
asterisks  indicate  p<0.0001  when
compared  to  the  control,  and  two
asterisks  indicate  p<0.001  when
compared to Ap4A alone.
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produced  a  long  delay  in  EMR  (1.03%±0.08%;  p<0.05),
increasing the time for closure to 109 h. All these data reveal
the  involvement  of  P2Y2-R  on  the  in  vivo  migration  of
epithelial cells triggered by Ap4A.
DISCUSSION
Normal visual function depends on the ability of the cornea
to form a physical barrier against infections and mainly to
form  a  smooth  and  transparent  refractive  surface.  These
corneal properties are sustained by the renewal/wound healing
process. The involvement of P2Y2-R and P2Y4-R in corneal
wound healing has been previously suggested by our and other
groups  through  pharmacological  tools  [4,6,23,24].
Furthermore,  the  presence  of  these  receptors  on  corneal
epithelial cells has been reported by immunohistochemical
and in situ hybridization techniques [25,26].
The  pharmacological  profile  of  P2Y2-R  subtypes  can
vary, depending on the species studied. Thus, there is a lack
of selective agonists/antagonists to prove the participation of
a specific P2Y-R in a cellular process [7-9].
In the current study, we extended our inquiry to determine
the  role  of  P2Y2-R  in  Ap4A-re-epithelialization  process
through  RNAi  technology.  The  RNAi  tool  has  been
successfully used for years to study gene function in the in
vitro and in vivo models. In this way, siRNAs against P2
receptors  have  been  previously  used  to  understand  its
physiologic roles [27-33].
Two siRNAs were designed from the previously cloned
rabbit P2Y2-R cDNA. Efficiency of siRNA transfection and
gene silencing was confirmed in SIRC cells. P2Y2-R siRNA
#2- protein knockdown was clearly observed by ICC assays.
In addition, both P2Y2-R siRNA #1 and P2Y2-R siRNA #2
reduce migration rates only in cells wounded and treated with
Ap4A. These results confirm the specific effect (on target) of
our P2Y2-R siRNAs.
We chose P2Y2-R siRNA #2 for in vivo assays because
of its greatest reduction in migration rate of cells treated with
Ap4A.
In  the  eye,  direct  application  of  siRNAs  has  been
performed and its potential use as an ocular therapeutic agent
has also been demonstrated [10,12]. To achieve high siRNA
Figure 5. Effect of P2Y2-R siRNA on Ap4A-mediated corneal wound healing. A: A representative sequence of the progress in the corneal
wound in the three different treatments (0.9% saline, 100 μM Ap4A, and siRNA+100 μM Ap4A) is shown. B: The graphs show the variation
of the wounded area versus time and the estimated migration rates (EMR) in the three treatments. An asterisk means p<0.05 when compared
to the control, and a double asterisk indicates p<0.01 when compared to the control.
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1176silencing efficacy in the in vivo models, it is critical not only
to  design  specific  siRNAs  but  also  to  choose  the  most
appropriate route of delivery. Between the ocular routes of
administration, we chose topical instillation because of our
target tissue (cornea). Topical instillation is a noninvasive
technique and lacks toxicity. Due to the corneal-protective
characteristics, we performed frequent instillations. However,
we  did  not  observe  changes  in  the  cornea  by  slit-lamp
biomicroscopy.
Efficiency of P2Y2-R silencing was also confirmed in
living animals by IHC and quantitative RT-PCR (qRT-PCR)
analysis. In addition, protein and mRNA reduction, ruled out
a  possible  microRNA  (miRNA)-related  translational
mechanism [10,34,35].
Our  IHC  results  reveal  that  after  wounding,  P2Y2-R
staining in Ap4A-treated wounds is less intense than in control
wounds. As with many other agonists (for example, insulin),
when Ap4A binds to its receptor, P2Y2-R, on the surface of  a
cell, the Ap4A-P2Y2-R complex undergoes endocytosis and is
subsequently attacked by intracellular lysosomal enzymes.
The internalization of the Ap4A molecules provides a pathway
for degradation of the Ap4A-P2Y2-R complex as well as for
regulation of the number of sites that are available for binding
on the cell’s surface. The rate of synthesis of new receptors
within the endoplasmic reticulum and their insertion in the
plasma  membrane  does  not  keep  pace  with  their  rate  of
destruction. Over time, this self-induced loss of target cell
receptors for Ap4A reduces the target cell’s sensitivity to the
elevated dinucleotide concentration [36,37].
In vivo corneal wound healing is a process that occurs in
three main steps: lag phase (from 0 h to 10 h after the wound),
migration phase (until 24–36 h after the wound), and mitosis
phase (lasting from 36 h after the wound to weeks) [38]. In
this manuscript, we have investigated the role of P2Y2-R in
the  Ap4A  acceleration  of  the  migration  rate  after  corneal
wound healing both in vitro and in vivo. The tested siRNA
performed its effect in the first 36 h after the wound, a period
that  correlates  with  the  migration  phase  that  we  have
investigated  in  this  manuscript.  Altogether,  these  results
confirm the role of P2Y2-R in corneal wound healing. As
indicated in our results, a selective siRNA against P2Y2-R
significantly blocked the ability of the dinucleotide Ap4A to
accelerate the rate of re-epithelialization after corneal scratch.
Preliminary  experiments  performed  in  our  laboratory
established that the application of Ap4A induces an increase
in  the  rate  of  migration  [4,6].  In  our  earlier  study  and
according to our pharmacological profile, we suggested a
P2Y2-R mechanism. In the present work, it seems clear that
wound healing effect evoked by Ap4A is due to activation of
P2Y2-R.
Demonstrating  the  presence  and  the  involvement  of
P2Y2-Rs in the corneal wound healing process will allow us
to develop compounds for the treatment of corneal wounds
and even for corneal repair after refractive surgery.
It  is  clear  that  selective  and  stable  compounds  are
necessary to produce a positive and sustained wound healing
process.  This  is  even  more  relevant  if  we  take  into
consideration the presence of enzymes cleaving nucleotides
in the ocular surface and the presence of other P2 receptors
delaying  corneal  wound  healing  [39].  In  this  context,  we
suggested  in  a  previous  work  possible  P2Y2-R/P2Y6-R
switches, which control the transition from wound healing
phase 2 to phase 3 [4,6]. More experiments will be necessary
to confirm this hypothesis and a possible approach is the use
of multi/individual-target siRNA.
In summary, the cloning and the design of a P2Y2-R
siRNA has allowed us to demonstrate the involvement of this
receptor in a relevant process such as corneal wound healing.
This demonstrates that the use of siRNA to silence proteins is
an interesting tool for receptors that do not have selective
antagonists to prove their participation in biochemical and
physiologic processes.
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